Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.

Publikation

Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.

Wissenschaftlicher Artikel/Review - 04.01.2024

Fehm Tanja N, Müller Volkmar, Banys-Paluchowski Maggie, Fasching Peter Andreas, Friedl Thomas Wolfram Paul, Hartkopf Andreas D, Huober Jens, Loehberg Christian R, Rack Brigitte, Riethdorf Sabine, Schneeweiss Andreas, Wallwiener Diethelm, Meier-Stiegen Franziska, Krawczyk Natalia, Jaeger Bernadette, Reinhardt Florian, Hoffmann Oliver, Müller Lothar, Wimberger Pauline, Ruckhäberle Eugen, Blohmer Jens-Uwe, Cieslik Jan-Philipp, Franken André, Niederacher Dieter, Neubauer Hans, Pantel Klaus, Janni Wolfgang, DETECT study group

Zitation

Fehm T, Müller V, Banys-Paluchowski M, Fasching P, Friedl T, Hartkopf A, Huober J, Loehberg C, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Krawczyk N, Jaeger B, Reinhardt F, Hoffmann O, Müller L, Wimberger P, Ruckhäberle E, Blohmer J, Cieslik J, Franken A, Niederacher D, Neubauer H, Pantel K, Janni W, DETECT study group. Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial. Clin Chem 2024; 70:307-318.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Clin Chem 2024; 70

Veröffentlichungsdatum

04.01.2024

eISSN (Online)

1530-8561

Seiten

307-318

Kurzbeschreibung/Zielsetzung

The phenotypes of tumor cells change during disease progression, but invasive rebiopsies of metastatic lesions are not always feasible. Here we aimed to determine whether initially HER2-negative metastatic breast cancer (MBC) patients with HER2-positive circulating tumor cells (CTCs) benefit from a HER2-targeted therapy.